Angel Comulada Rivera
Endocrinology, Diabetes & Metabolism · Bayamon, PRNPI 1669559803
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $25,275 of the $31,412 with a category attached, or 80.5%. Eli Lilly accounts for 81.3% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $13,449 and has fallen 67.6% since, to $4,359 in 2025. Among endocrinology, diabetes & metabolism clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $142.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$26K
- Medtronic$2K
- Boehringer Ingelheim$1K
- Sanofi-aventis U.S. LLC$928
- Johnson & Johnson$699
- Dexcom, Inc.$370
- plus $757 from 9 others
Across 1,024 payments — averaging $8849.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$4.5M
- Eli Lilly$3.1M
- Boehringer Ingelheim$877K
- Novartis$300K
- Alnylam Pharmaceuticals Inc.$160K
- Novo Nordisk AS$91K
- plus $34K from 2 others
What the payments were for
- Travel & lodging$25,27580%
- Food & beverage$6,13220%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 148 | $25,540 |
| Medtronic(2 entities) | 9 | $2,096 |
| Boehringer Ingelheim | 7 | $1,023 |
| Sanofi-aventis U.S. LLC | 12 | $928 |
| Johnson & Johnson | 11 | $699 |
| Dexcom, Inc. | 6 | $370 |
| Merck | 7 | $261 |
| AstraZeneca | 7 | $109 |
| Lilly USA, LLC | 1 | $100 |
| Eli Lilly Export S.A. Puerto Rico Branch | 2 | $90 |
| Novo Nordisk | 4 | $74 |
| PBG Puerto Rico LLC | 2 | $42 |
| Abbott | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Novartis | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,764
- TOUJEO$544
- SOLIQUA 100/33$544
- TZIELD$290
- TRULICITY$173
- LANTUS$126
- DEXCOM G7 GSS (161)$121
- DEXCOM G6 TRANSMITTER$113
- DEXCOM CGM$102
- XARELTO$100
- STEGLATRO$100
- JARDIANCE$100
How this compares
$31,412 in reported general payments places this provider in the 90th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 79 | $96,007 |
| FarxigaDapagliflozin Propanediol | 36 | $48,067 |
| JardianceEmpagliflozin | 37 | $46,249 |
| OzempicSemaglutide | 21 | $38,949 |
| SynthroidLevothyroxine Sodium | 253 | $31,252 |
| JanuviaSitagliptin Phosphate | 20 | $26,999 |
| TradjentaLinagliptin | 23 | $26,118 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 26 | $17,827 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $16,594 |
| Jentadueto XrLinagliptin/Metformin Hcl | 20 | $16,386 |
| SynjardyEmpagliflozin/Metformin Hcl | 11 | $11,491 |
| LantusInsulin Glargine,hum.Rec.Anlog | 41 | $6,160 |
| CrestorRosuvastatin Calcium | 12 | $3,362 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,438 |
| HumalogInsulin Lispro | 14 | $2,156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Jentadueto Xr, Synjardy | $1,023 | $116,838104 claims |
| Lilly USA, LLCTrulicity, Humalog | $100 | $98,16393 claims |
| AstraZenecaFarxiga, Crestor | $109 | $51,42948 claims |
| MerckJanuvia, Janumet Xr | $261 | $44,82646 claims |
| Novo NordiskOzempic | $74 | $38,94921 claims |
| Sanofi-aventis U.S. LLCLantus | $928 | $6,16041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Bayamon
- Altagracia Alcantara GonzalezBayamon$58K
- Jean Pujals KuryBayamon$50K
- Paola Mansilla-LetelierBayamon$33K
- Gloria Vega CarattiniBayamon$26K
- Hiram Maldonado RiveraBayamon$7K
- Jose Garcia MateoPonce$945K
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.